Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of inhibiting ~~a receptor tyrosine kinase (RTK)~~ VEGFR-2 in a mammal comprising administering an extracellular ~~RTK~~ VEGFR-2 antagonist and an intracellular ~~RTK antagonists~~ VEGFR-2 antagonist to the mammal.

2. (original) The method of claim 1, wherein the method is used to treat a tumor growth or angiogenesis in the mammal.

3-8. (canceled)

9. (currently amended) The method of claim ~~8~~ 25, wherein the extracellular ~~RTK~~ VEGFR-2 antagonist is bevacizumab.

10. (canceled)

11. (previously presented) The method of claim 1 or 2, wherein the method further comprises administrating an antineoplastic agent.

12-21. (canceled)

22. (new) The method of claim 1 or 2, wherein the extracellular VEGFR-2 antagonist is a biological molecule.

23. (new) The method of claim 1 or 2, wherein the extracellular VEGFR-2 antagonist is a monoclonal antibody that binds to VEGFR-2.

24. (new) The method of claim 23, wherein the monoclonal antibody is IMC-1C11.

25. (new) The method of claim 1 or 2, wherein the extracellular VEGFR-2 antagonist is a monoclonal antibody that binds to VEGF.

26. (new) The method of claim 1 or 2, wherein the intracellular VEGFR-2 antagonist is a small molecule.

27. (new) The method of claim 26, wherein the small molecule competes with ATP for binding to the intracellular domain of VEGFR-2.

28. (new) The method of claim 26, wherein the small molecule is ZD-6474.